Creative Medical CEO: ‘momentum’ towards commercialization ‘continuing to build’

“As we enter the second half of 2024, it is an opportune time to reflect on our recent achievements,” said Timothy Warbington, CEO. “Many of our successes thus far in 2024 were the result of investments we have made in prior years combined with our steadfast adherence to operating a lean corporate structure, and engaging with our global partners and institutions to support the rapid translation of novel therapies into patients. Momentum in advancing our proprietary, cell-based therapies towards commercialization is continuing to build. We believe that these novel therapies have the potential to address critical unmet medical needs, including for the treatment of Type 1 Diabetes and Chronic Lower Back Pain. We have: Manufactured over six billion AlloStemTM clinical-grade cells at a cGMP facility that are being utilized for clinical trials. Developed and filed a Drug Master File with the FDA, which accelerates the Investigational New Drug filing and approval process and eliminates the need for costly and redundant regulatory filings. Received FDA clearance of two IND applications and an expanded access therapy within 30 days of filing. Received Orphan Drug Designation from the FDA for CELZ-101, or ImmCelz for Brittle Type 1 Diabetes. On-track to complete patient recruitment for our clinical trials over a 1 to 2-year horizon. With each new accomplishment, I am grateful for the strength of our programs, the dedication of our employees and partners, the opportunities inherent in our addressable markets and most importantly the patients who volunteer for our clinical trials…The Company expects to report cash of approximately $7.5 million and no long-term debt as-of June 30, 2024. The Company believes it has sufficient funds to meet its anticipated operating costs and capital expenditure requirements through at least Q2 2025…We have remained focused on maintaining a strong financial position and respecting the investment of our shareholders by allocating our resources prudently, limiting our annual cash burn, and avoiding unnecessary dilution. We will continue to concentrate on pioneering and translating new approaches to treat disease. To that end, should the need arise to raise additional capital in pursuit of this objective, we will do so in a manner that aligns with our commitment to deliver long-term shareholder value. Our current capital structure limits our ability to do this, and we therefore appreciate the support of shareholders in voting FOR Proposal Two.”